Market Overview

Report: Merck Searching Internally For Next CEO

Report: Merck Searching Internally For Next CEO

Merck & Co., Inc. (NYSE: MRK) is preparing for the departure of its CEO Kenneth Frazier and searching internally for a replacement, according to Bloomberg.

In May, Merck announced an agreement to acquire the clinical-stage biopharmaceutical company Peloton Therapeutics for $1.05 billion cash upfront and a further $1.15 billion if certain regulatory and sales milestones are reached.

On Wednesday, Merck & Co shares are trading up 0.19% at $84.66.

Related Links:

The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut

Merck To Buy Clinical-Stage Biopharma Peloton Therapeutics For More Than $1B

Photo courtesy of Merck. 

Posted-In: BloombergNews Health Care Management Media General Best of Benzinga


Related Articles (MRK)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

'Murder Mystery' May Have Set A Netflix Viewing Record

Tripadvisor Gets An Upgrade On Its Underappreciated Experiences Segment